nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—ABCB1—ovarian cancer	0.358	1	CbGaD
Pomalidomide—ABCB1—Topotecan—ovarian cancer	0.0532	0.221	CbGbCtD
Pomalidomide—ABCB1—Vinorelbine—ovarian cancer	0.0375	0.156	CbGbCtD
Pomalidomide—CYP3A4—Topotecan—ovarian cancer	0.0319	0.133	CbGbCtD
Pomalidomide—ABCB1—Paclitaxel—ovarian cancer	0.0263	0.11	CbGbCtD
Pomalidomide—CYP3A4—Vinorelbine—ovarian cancer	0.0225	0.0935	CbGbCtD
Pomalidomide—ABCB1—Docetaxel—ovarian cancer	0.0191	0.0792	CbGbCtD
Pomalidomide—CYP3A4—Paclitaxel—ovarian cancer	0.0158	0.0657	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—ovarian cancer	0.0142	0.0591	CbGbCtD
Pomalidomide—CYP3A4—Docetaxel—ovarian cancer	0.0114	0.0475	CbGbCtD
Pomalidomide—PTGS2—ovarian follicle—ovarian cancer	0.00855	0.121	CbGeAlD
Pomalidomide—CYP3A4—Doxorubicin—ovarian cancer	0.00851	0.0354	CbGbCtD
Pomalidomide—TNF—vagina—ovarian cancer	0.00487	0.0691	CbGeAlD
Pomalidomide—CRBN—myometrium—ovarian cancer	0.00441	0.0626	CbGeAlD
Pomalidomide—CRBN—embryo—ovarian cancer	0.00424	0.0603	CbGeAlD
Pomalidomide—CRBN—uterine cervix—ovarian cancer	0.00343	0.0488	CbGeAlD
Pomalidomide—CRBN—decidua—ovarian cancer	0.00327	0.0464	CbGeAlD
Pomalidomide—TNF—lymph node—ovarian cancer	0.00315	0.0447	CbGeAlD
Pomalidomide—CRBN—endometrium—ovarian cancer	0.00311	0.0441	CbGeAlD
Pomalidomide—CRBN—gonad—ovarian cancer	0.00288	0.0409	CbGeAlD
Pomalidomide—CRBN—uterus—ovarian cancer	0.00286	0.0406	CbGeAlD
Pomalidomide—CRBN—female reproductive system—ovarian cancer	0.00257	0.0365	CbGeAlD
Pomalidomide—CRBN—bone marrow—ovarian cancer	0.00243	0.0345	CbGeAlD
Pomalidomide—CRBN—female gonad—ovarian cancer	0.00234	0.0332	CbGeAlD
Pomalidomide—CRBN—vagina—ovarian cancer	0.00233	0.033	CbGeAlD
Pomalidomide—CRBN—testis—ovarian cancer	0.00208	0.0295	CbGeAlD
Pomalidomide—CRBN—lymph node—ovarian cancer	0.0015	0.0214	CbGeAlD
Pomalidomide—Lenalidomide—ABCB1—ovarian cancer	0.00127	1	CrCbGaD
Pomalidomide—PTGS2—myometrium—ovarian cancer	0.0012	0.0171	CbGeAlD
Pomalidomide—PTGS2—embryo—ovarian cancer	0.00116	0.0164	CbGeAlD
Pomalidomide—PTGS2—epithelium—ovarian cancer	0.000943	0.0134	CbGeAlD
Pomalidomide—PTGS2—uterine cervix—ovarian cancer	0.000935	0.0133	CbGeAlD
Pomalidomide—PTGS2—endometrium—ovarian cancer	0.000846	0.012	CbGeAlD
Pomalidomide—PTGS2—uterus—ovarian cancer	0.000779	0.0111	CbGeAlD
Pomalidomide—ABCB1—myometrium—ovarian cancer	0.000743	0.0106	CbGeAlD
Pomalidomide—ABCB1—embryo—ovarian cancer	0.000715	0.0101	CbGeAlD
Pomalidomide—PTGS2—female reproductive system—ovarian cancer	0.0007	0.00995	CbGeAlD
Pomalidomide—PTGS2—bone marrow—ovarian cancer	0.000661	0.00939	CbGeAlD
Pomalidomide—PTGS2—female gonad—ovarian cancer	0.000637	0.00905	CbGeAlD
Pomalidomide—PTGS2—vagina—ovarian cancer	0.000633	0.009	CbGeAlD
Pomalidomide—CYP3A4—female reproductive system—ovarian cancer	0.000612	0.00869	CbGeAlD
Pomalidomide—ABCB1—epithelium—ovarian cancer	0.000583	0.00828	CbGeAlD
Pomalidomide—ABCB1—uterine cervix—ovarian cancer	0.000578	0.00821	CbGeAlD
Pomalidomide—ABCB1—decidua—ovarian cancer	0.000551	0.00782	CbGeAlD
Pomalidomide—ABCB1—endometrium—ovarian cancer	0.000523	0.00743	CbGeAlD
Pomalidomide—ABCB1—gonad—ovarian cancer	0.000485	0.00689	CbGeAlD
Pomalidomide—ABCB1—uterus—ovarian cancer	0.000482	0.00684	CbGeAlD
Pomalidomide—ABCB1—female reproductive system—ovarian cancer	0.000433	0.00615	CbGeAlD
Pomalidomide—PTGS2—lymph node—ovarian cancer	0.00041	0.00582	CbGeAlD
Pomalidomide—ABCB1—bone marrow—ovarian cancer	0.000409	0.00581	CbGeAlD
Pomalidomide—ABCB1—female gonad—ovarian cancer	0.000394	0.0056	CbGeAlD
Pomalidomide—ABCB1—vagina—ovarian cancer	0.000392	0.00556	CbGeAlD
Pomalidomide—ABCB1—testis—ovarian cancer	0.00035	0.00497	CbGeAlD
Pomalidomide—Vomiting—Chlorambucil—ovarian cancer	0.000273	0.00112	CcSEcCtD
Pomalidomide—Mental disorder—Paclitaxel—ovarian cancer	0.000271	0.00112	CcSEcCtD
Pomalidomide—Pruritus—Topotecan—ovarian cancer	0.00027	0.00111	CcSEcCtD
Pomalidomide—Malnutrition—Paclitaxel—ovarian cancer	0.000269	0.00111	CcSEcCtD
Pomalidomide—Feeling abnormal—Vinorelbine—ovarian cancer	0.000269	0.00111	CcSEcCtD
Pomalidomide—Asthenia—Melphalan—ovarian cancer	0.000268	0.0011	CcSEcCtD
Pomalidomide—Pruritus—Melphalan—ovarian cancer	0.000265	0.00109	CcSEcCtD
Pomalidomide—Diarrhoea—Topotecan—ovarian cancer	0.000261	0.00108	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000261	0.00107	CcSEcCtD
Pomalidomide—Back pain—Paclitaxel—ovarian cancer	0.000261	0.00107	CcSEcCtD
Pomalidomide—Urinary tract disorder—Docetaxel—ovarian cancer	0.000259	0.00107	CcSEcCtD
Pomalidomide—Muscle spasms—Paclitaxel—ovarian cancer	0.000259	0.00107	CcSEcCtD
Pomalidomide—Body temperature increased—Vinorelbine—ovarian cancer	0.000258	0.00106	CcSEcCtD
Pomalidomide—Oedema peripheral—Docetaxel—ovarian cancer	0.000258	0.00106	CcSEcCtD
Pomalidomide—Connective tissue disorder—Docetaxel—ovarian cancer	0.000258	0.00106	CcSEcCtD
Pomalidomide—Urethral disorder—Docetaxel—ovarian cancer	0.000257	0.00106	CcSEcCtD
Pomalidomide—Hyponatraemia—Epirubicin—ovarian cancer	0.000257	0.00106	CcSEcCtD
Pomalidomide—Diarrhoea—Melphalan—ovarian cancer	0.000256	0.00105	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—ovarian cancer	0.000256	0.00105	CcSEcCtD
Pomalidomide—Nausea—Chlorambucil—ovarian cancer	0.000255	0.00105	CcSEcCtD
Pomalidomide—ABCB1—lymph node—ovarian cancer	0.000253	0.0036	CbGeAlD
Pomalidomide—Dizziness—Topotecan—ovarian cancer	0.000253	0.00104	CcSEcCtD
Pomalidomide—Tremor—Paclitaxel—ovarian cancer	0.000252	0.00104	CcSEcCtD
Pomalidomide—Anaemia—Paclitaxel—ovarian cancer	0.000249	0.00102	CcSEcCtD
Pomalidomide—Cardiac disorder—Docetaxel—ovarian cancer	0.000243	0.001	CcSEcCtD
Pomalidomide—Vomiting—Topotecan—ovarian cancer	0.000243	0.000999	CcSEcCtD
Pomalidomide—Vertigo—Paclitaxel—ovarian cancer	0.000242	0.000996	CcSEcCtD
Pomalidomide—Leukopenia—Paclitaxel—ovarian cancer	0.000241	0.000992	CcSEcCtD
Pomalidomide—Rash—Topotecan—ovarian cancer	0.000241	0.000991	CcSEcCtD
Pomalidomide—Hypersensitivity—Vinorelbine—ovarian cancer	0.000241	0.000991	CcSEcCtD
Pomalidomide—Dermatitis—Topotecan—ovarian cancer	0.000241	0.00099	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—ovarian cancer	0.00024	0.000986	CcSEcCtD
Pomalidomide—Headache—Topotecan—ovarian cancer	0.000239	0.000985	CcSEcCtD
Pomalidomide—Angiopathy—Docetaxel—ovarian cancer	0.000238	0.000979	CcSEcCtD
Pomalidomide—Vomiting—Melphalan—ovarian cancer	0.000238	0.000979	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—ovarian cancer	0.000238	0.000978	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—ovarian cancer	0.000238	0.000977	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—ovarian cancer	0.000237	0.000973	CcSEcCtD
Pomalidomide—Mediastinal disorder—Docetaxel—ovarian cancer	0.000236	0.000972	CcSEcCtD
Pomalidomide—Rash—Melphalan—ovarian cancer	0.000236	0.00097	CcSEcCtD
Pomalidomide—Dermatitis—Melphalan—ovarian cancer	0.000236	0.00097	CcSEcCtD
Pomalidomide—Chills—Docetaxel—ovarian cancer	0.000235	0.000968	CcSEcCtD
Pomalidomide—Cough—Paclitaxel—ovarian cancer	0.000235	0.000967	CcSEcCtD
Pomalidomide—Asthenia—Vinorelbine—ovarian cancer	0.000235	0.000965	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—ovarian cancer	0.000234	0.000964	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—ovarian cancer	0.000233	0.000957	CcSEcCtD
Pomalidomide—Pruritus—Vinorelbine—ovarian cancer	0.000231	0.000951	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—ovarian cancer	0.000231	0.000951	CcSEcCtD
Pomalidomide—Mental disorder—Docetaxel—ovarian cancer	0.00023	0.000945	CcSEcCtD
Pomalidomide—Arthralgia—Paclitaxel—ovarian cancer	0.000229	0.000943	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—ovarian cancer	0.000229	0.000941	CcSEcCtD
Pomalidomide—Anxiety—Paclitaxel—ovarian cancer	0.000229	0.00094	CcSEcCtD
Pomalidomide—Malnutrition—Docetaxel—ovarian cancer	0.000228	0.000939	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000228	0.000937	CcSEcCtD
Pomalidomide—Nausea—Topotecan—ovarian cancer	0.000227	0.000934	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000226	0.000928	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—ovarian cancer	0.000226	0.000928	CcSEcCtD
Pomalidomide—Diarrhoea—Vinorelbine—ovarian cancer	0.000224	0.00092	CcSEcCtD
Pomalidomide—Nausea—Melphalan—ovarian cancer	0.000222	0.000914	CcSEcCtD
Pomalidomide—Confusional state—Paclitaxel—ovarian cancer	0.000222	0.000912	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000222	0.000912	CcSEcCtD
Pomalidomide—Back pain—Docetaxel—ovarian cancer	0.000221	0.000909	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—ovarian cancer	0.00022	0.000905	CcSEcCtD
Pomalidomide—Muscle spasms—Docetaxel—ovarian cancer	0.00022	0.000903	CcSEcCtD
Pomalidomide—Infection—Paclitaxel—ovarian cancer	0.000218	0.000899	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—ovarian cancer	0.000217	0.000892	CcSEcCtD
Pomalidomide—Dizziness—Vinorelbine—ovarian cancer	0.000216	0.000889	CcSEcCtD
Pomalidomide—Nervous system disorder—Paclitaxel—ovarian cancer	0.000216	0.000887	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—ovarian cancer	0.000215	0.000886	CcSEcCtD
Pomalidomide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000215	0.000886	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—ovarian cancer	0.000214	0.00088	CcSEcCtD
Pomalidomide—Skin disorder—Paclitaxel—ovarian cancer	0.000214	0.000879	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—ovarian cancer	0.000213	0.000874	CcSEcCtD
Pomalidomide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000213	0.000874	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000212	0.00087	CcSEcCtD
Pomalidomide—Anaemia—Docetaxel—ovarian cancer	0.000211	0.000868	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—ovarian cancer	0.00021	0.000864	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—ovarian cancer	0.000209	0.000859	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000209	0.000859	CcSEcCtD
Pomalidomide—Vomiting—Vinorelbine—ovarian cancer	0.000208	0.000855	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—ovarian cancer	0.000207	0.00085	CcSEcCtD
Pomalidomide—Rash—Vinorelbine—ovarian cancer	0.000206	0.000848	CcSEcCtD
Pomalidomide—Dermatitis—Vinorelbine—ovarian cancer	0.000206	0.000847	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000205	0.000845	CcSEcCtD
Pomalidomide—Headache—Vinorelbine—ovarian cancer	0.000205	0.000842	CcSEcCtD
Pomalidomide—Leukopenia—Docetaxel—ovarian cancer	0.000204	0.000841	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—ovarian cancer	0.000201	0.000828	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.0002	0.000824	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—ovarian cancer	0.0002	0.000823	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000199	0.00082	CcSEcCtD
Pomalidomide—Cough—Docetaxel—ovarian cancer	0.000199	0.00082	CcSEcCtD
Pomalidomide—Insomnia—Paclitaxel—ovarian cancer	0.000199	0.000818	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—ovarian cancer	0.000198	0.000815	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—ovarian cancer	0.000197	0.000811	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—ovarian cancer	0.000197	0.000811	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—ovarian cancer	0.000197	0.000809	CcSEcCtD
Pomalidomide—Dyspnoea—Paclitaxel—ovarian cancer	0.000196	0.000806	CcSEcCtD
Pomalidomide—Arthralgia—Docetaxel—ovarian cancer	0.000194	0.0008	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—ovarian cancer	0.000194	0.000799	CcSEcCtD
Pomalidomide—Nausea—Vinorelbine—ovarian cancer	0.000194	0.000799	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—ovarian cancer	0.000194	0.000797	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000193	0.000795	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000193	0.000794	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—ovarian cancer	0.000192	0.000788	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—ovarian cancer	0.000191	0.000787	CcSEcCtD
Pomalidomide—Decreased appetite—Paclitaxel—ovarian cancer	0.000191	0.000786	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00019	0.000782	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00019	0.000781	CcSEcCtD
Pomalidomide—Fatigue—Paclitaxel—ovarian cancer	0.00019	0.00078	CcSEcCtD
Pomalidomide—Pain—Paclitaxel—ovarian cancer	0.000188	0.000773	CcSEcCtD
Pomalidomide—Constipation—Paclitaxel—ovarian cancer	0.000188	0.000773	CcSEcCtD
Pomalidomide—Confusional state—Docetaxel—ovarian cancer	0.000188	0.000773	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000186	0.000767	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—ovarian cancer	0.000186	0.000766	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—ovarian cancer	0.000186	0.000765	CcSEcCtD
Pomalidomide—Infection—Docetaxel—ovarian cancer	0.000185	0.000762	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—ovarian cancer	0.000185	0.000761	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000185	0.000759	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—ovarian cancer	0.000183	0.000755	CcSEcCtD
Pomalidomide—Nervous system disorder—Docetaxel—ovarian cancer	0.000183	0.000752	CcSEcCtD
Pomalidomide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000182	0.000751	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—ovarian cancer	0.000182	0.00075	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—ovarian cancer	0.000182	0.00075	CcSEcCtD
Pomalidomide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000181	0.000745	CcSEcCtD
Pomalidomide—Skin disorder—Docetaxel—ovarian cancer	0.000181	0.000745	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—ovarian cancer	0.000179	0.000737	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000179	0.000735	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000177	0.000729	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—ovarian cancer	0.000175	0.000719	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—ovarian cancer	0.000174	0.000717	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—ovarian cancer	0.000174	0.000715	CcSEcCtD
Pomalidomide—Body temperature increased—Paclitaxel—ovarian cancer	0.000174	0.000715	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—ovarian cancer	0.000173	0.000713	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000172	0.000709	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—ovarian cancer	0.000172	0.000708	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00017	0.000698	CcSEcCtD
Pomalidomide—Insomnia—Docetaxel—ovarian cancer	0.000169	0.000693	CcSEcCtD
Pomalidomide—Dyspnoea—Docetaxel—ovarian cancer	0.000166	0.000683	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—ovarian cancer	0.000164	0.000675	CcSEcCtD
Pomalidomide—Decreased appetite—Docetaxel—ovarian cancer	0.000162	0.000666	CcSEcCtD
Pomalidomide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000162	0.000666	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000162	0.000665	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000161	0.000663	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000161	0.000662	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000161	0.000662	CcSEcCtD
Pomalidomide—Fatigue—Docetaxel—ovarian cancer	0.000161	0.000661	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—ovarian cancer	0.000161	0.00066	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—ovarian cancer	0.000161	0.00066	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—ovarian cancer	0.000159	0.000656	CcSEcCtD
Pomalidomide—Pain—Docetaxel—ovarian cancer	0.000159	0.000656	CcSEcCtD
Pomalidomide—Constipation—Docetaxel—ovarian cancer	0.000159	0.000656	CcSEcCtD
Pomalidomide—Chills—Epirubicin—ovarian cancer	0.000159	0.000653	CcSEcCtD
Pomalidomide—Asthenia—Paclitaxel—ovarian cancer	0.000158	0.000649	CcSEcCtD
Pomalidomide—Pruritus—Paclitaxel—ovarian cancer	0.000156	0.00064	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—ovarian cancer	0.000155	0.000638	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—ovarian cancer	0.000154	0.000634	CcSEcCtD
Pomalidomide—Feeling abnormal—Docetaxel—ovarian cancer	0.000154	0.000632	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—ovarian cancer	0.000152	0.000625	CcSEcCtD
Pomalidomide—Diarrhoea—Paclitaxel—ovarian cancer	0.00015	0.000619	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—ovarian cancer	0.000149	0.000613	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—ovarian cancer	0.000149	0.000611	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—ovarian cancer	0.000148	0.000609	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000148	0.000607	CcSEcCtD
Pomalidomide—Body temperature increased—Docetaxel—ovarian cancer	0.000147	0.000606	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—ovarian cancer	0.000147	0.000604	CcSEcCtD
Pomalidomide—Dizziness—Paclitaxel—ovarian cancer	0.000145	0.000598	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—ovarian cancer	0.000143	0.00059	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—ovarian cancer	0.000143	0.000586	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—ovarian cancer	0.000142	0.000586	CcSEcCtD
Pomalidomide—Vomiting—Paclitaxel—ovarian cancer	0.00014	0.000575	CcSEcCtD
Pomalidomide—Rash—Paclitaxel—ovarian cancer	0.000139	0.00057	CcSEcCtD
Pomalidomide—Dermatitis—Paclitaxel—ovarian cancer	0.000139	0.00057	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—ovarian cancer	0.000138	0.000569	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—ovarian cancer	0.000138	0.000567	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—ovarian cancer	0.000138	0.000567	CcSEcCtD
Pomalidomide—Headache—Paclitaxel—ovarian cancer	0.000138	0.000567	CcSEcCtD
Pomalidomide—Hypersensitivity—Docetaxel—ovarian cancer	0.000137	0.000565	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—ovarian cancer	0.000137	0.000564	CcSEcCtD
Pomalidomide—Cough—Epirubicin—ovarian cancer	0.000134	0.000553	CcSEcCtD
Pomalidomide—Asthenia—Docetaxel—ovarian cancer	0.000134	0.00055	CcSEcCtD
Pomalidomide—Pruritus—Docetaxel—ovarian cancer	0.000132	0.000542	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—ovarian cancer	0.000132	0.000542	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—ovarian cancer	0.000131	0.000539	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—ovarian cancer	0.000131	0.000538	CcSEcCtD
Pomalidomide—Nausea—Paclitaxel—ovarian cancer	0.000131	0.000537	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00013	0.000536	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—ovarian cancer	0.000128	0.000527	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—ovarian cancer	0.000128	0.000525	CcSEcCtD
Pomalidomide—Diarrhoea—Docetaxel—ovarian cancer	0.000128	0.000525	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—ovarian cancer	0.000127	0.000521	CcSEcCtD
Pomalidomide—Infection—Epirubicin—ovarian cancer	0.000125	0.000514	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—ovarian cancer	0.000124	0.000512	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—ovarian cancer	0.000123	0.000507	CcSEcCtD
Pomalidomide—Dizziness—Docetaxel—ovarian cancer	0.000123	0.000507	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000123	0.000506	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—ovarian cancer	0.000122	0.000502	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000122	0.0005	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—ovarian cancer	0.000121	0.000499	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—ovarian cancer	0.000121	0.000497	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000121	0.000496	CcSEcCtD
Pomalidomide—Vomiting—Docetaxel—ovarian cancer	0.000119	0.000487	CcSEcCtD
Pomalidomide—Rash—Docetaxel—ovarian cancer	0.000118	0.000483	CcSEcCtD
Pomalidomide—Dermatitis—Docetaxel—ovarian cancer	0.000117	0.000483	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—ovarian cancer	0.000117	0.000482	CcSEcCtD
Pomalidomide—Headache—Docetaxel—ovarian cancer	0.000117	0.00048	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—ovarian cancer	0.000116	0.000475	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000115	0.000471	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—ovarian cancer	0.000114	0.000469	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000114	0.000468	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—ovarian cancer	0.000114	0.000468	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—ovarian cancer	0.000113	0.000465	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000112	0.000463	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—ovarian cancer	0.000112	0.000461	CcSEcCtD
Pomalidomide—Nausea—Docetaxel—ovarian cancer	0.000111	0.000455	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—ovarian cancer	0.000109	0.000449	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000109	0.000446	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—ovarian cancer	0.000108	0.000446	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—ovarian cancer	0.000108	0.000442	CcSEcCtD
Pomalidomide—Pain—Epirubicin—ovarian cancer	0.000108	0.000442	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000106	0.000436	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—ovarian cancer	0.000105	0.000433	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—ovarian cancer	0.000104	0.000427	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—ovarian cancer	0.000104	0.000426	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—ovarian cancer	0.000101	0.000416	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.0001	0.000413	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—ovarian cancer	0.0001	0.000412	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—ovarian cancer	9.95e-05	0.000409	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—ovarian cancer	9.95e-05	0.000409	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—ovarian cancer	9.94e-05	0.000409	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—ovarian cancer	9.59e-05	0.000394	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—ovarian cancer	9.26e-05	0.000381	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—ovarian cancer	9.2e-05	0.000378	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—ovarian cancer	9.02e-05	0.000371	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—ovarian cancer	8.89e-05	0.000366	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—ovarian cancer	8.6e-05	0.000354	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—ovarian cancer	8.57e-05	0.000352	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—ovarian cancer	8.35e-05	0.000343	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—ovarian cancer	8.31e-05	0.000342	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—ovarian cancer	8.23e-05	0.000338	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—ovarian cancer	7.99e-05	0.000329	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—ovarian cancer	7.96e-05	0.000327	CcSEcCtD
Pomalidomide—Rash—Epirubicin—ovarian cancer	7.93e-05	0.000326	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—ovarian cancer	7.92e-05	0.000326	CcSEcCtD
Pomalidomide—Headache—Epirubicin—ovarian cancer	7.88e-05	0.000324	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—ovarian cancer	7.69e-05	0.000316	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—ovarian cancer	7.47e-05	0.000307	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—ovarian cancer	7.4e-05	0.000304	CcSEcCtD
Pomalidomide—PTGS2—Metabolism—NME2—ovarian cancer	7.34e-05	0.00085	CbGpPWpGaD
Pomalidomide—Rash—Doxorubicin—ovarian cancer	7.33e-05	0.000302	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—ovarian cancer	7.33e-05	0.000301	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.29e-05	0.000844	CbGpPWpGaD
Pomalidomide—Headache—Doxorubicin—ovarian cancer	7.29e-05	0.0003	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—ovarian cancer	7.28e-05	0.000842	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—ovarian cancer	7.26e-05	0.000841	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	7.22e-05	0.000836	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	7.12e-05	0.000824	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—ovarian cancer	7.06e-05	0.000817	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.04e-05	0.000815	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	6.98e-05	0.000808	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—ovarian cancer	6.96e-05	0.000806	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	6.96e-05	0.000805	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	6.95e-05	0.000805	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	6.95e-05	0.000805	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	6.95e-05	0.000805	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—ovarian cancer	6.91e-05	0.000284	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	6.87e-05	0.000795	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	6.82e-05	0.000789	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	6.81e-05	0.000789	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	6.8e-05	0.000787	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	6.72e-05	0.000778	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—ovarian cancer	6.7e-05	0.000776	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	6.68e-05	0.000773	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK3—ovarian cancer	6.67e-05	0.000772	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	6.66e-05	0.000771	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP3—ovarian cancer	6.66e-05	0.000771	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL2—ovarian cancer	6.65e-05	0.000769	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BCL9—ovarian cancer	6.65e-05	0.000769	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	6.63e-05	0.000768	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	6.58e-05	0.000761	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	6.52e-05	0.000755	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—ovarian cancer	6.48e-05	0.00075	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	6.47e-05	0.000748	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—ovarian cancer	6.46e-05	0.000748	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	6.45e-05	0.000747	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	6.44e-05	0.000745	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—ovarian cancer	6.4e-05	0.000741	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.39e-05	0.00074	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	6.38e-05	0.000739	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.36e-05	0.000736	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	6.35e-05	0.000735	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MAPK1—ovarian cancer	6.34e-05	0.000734	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—ovarian cancer	6.34e-05	0.000734	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.26e-05	0.000724	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	6.25e-05	0.000724	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.25e-05	0.000724	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.23e-05	0.000721	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.01e-05	0.000696	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—ovarian cancer	5.99e-05	0.000693	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—ovarian cancer	5.98e-05	0.000692	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	5.91e-05	0.000684	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	5.85e-05	0.000677	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.72e-05	0.000662	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.72e-05	0.000662	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—ovarian cancer	5.68e-05	0.000657	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—ovarian cancer	5.67e-05	0.000656	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	5.65e-05	0.000654	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	5.48e-05	0.000635	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	5.47e-05	0.000633	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.41e-05	0.000626	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—ovarian cancer	5.32e-05	0.000616	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	5.32e-05	0.000616	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MET—ovarian cancer	5.28e-05	0.000611	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	5.26e-05	0.000609	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.26e-05	0.000608	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—ovarian cancer	5.23e-05	0.000606	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NME2—ovarian cancer	5.21e-05	0.000603	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	5.2e-05	0.000602	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	5.2e-05	0.000602	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	5.19e-05	0.000601	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6ST—ovarian cancer	5.17e-05	0.000599	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—ovarian cancer	5.17e-05	0.000599	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	5.11e-05	0.000591	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.08e-05	0.000588	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	5.06e-05	0.000585	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	5.05e-05	0.000584	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	5.02e-05	0.000581	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.97e-05	0.000575	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PPP1CC—ovarian cancer	4.94e-05	0.000572	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	4.93e-05	0.000571	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.8e-05	0.000556	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—ovarian cancer	4.79e-05	0.000555	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYTB—ovarian cancer	4.73e-05	0.000548	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.73e-05	0.000547	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.66e-05	0.00054	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.63e-05	0.000536	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.63e-05	0.000535	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.51e-05	0.000522	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—ovarian cancer	4.5e-05	0.00052	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.47e-05	0.000517	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—ovarian cancer	4.4e-05	0.00051	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	4.37e-05	0.000506	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.35e-05	0.000504	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	4.16e-05	0.000482	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NME2—ovarian cancer	4.16e-05	0.000481	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPP1CC—ovarian cancer	4.14e-05	0.000479	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BRIP1—ovarian cancer	4.14e-05	0.000479	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.06e-05	0.00047	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	4e-05	0.000463	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.93e-05	0.000455	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—ovarian cancer	3.86e-05	0.000447	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC6—ovarian cancer	3.74e-05	0.000433	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.72e-05	0.000431	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.62e-05	0.000419	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.62e-05	0.000419	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.54e-05	0.00041	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.54e-05	0.00041	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.53e-05	0.000408	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—ovarian cancer	3.38e-05	0.000391	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.37e-05	0.00039	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYTB—ovarian cancer	3.35e-05	0.000388	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.35e-05	0.000388	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.34e-05	0.000387	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—ovarian cancer	3.31e-05	0.000383	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.29e-05	0.00038	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.25e-05	0.000376	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—XIAP—ovarian cancer	3.25e-05	0.000376	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NME2—ovarian cancer	3.21e-05	0.000371	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.2e-05	0.00037	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.17e-05	0.000367	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SMARCA4—ovarian cancer	3.16e-05	0.000366	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EREG—ovarian cancer	3.09e-05	0.000357	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.09e-05	0.000357	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.07e-05	0.000356	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.01e-05	0.000349	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—ovarian cancer	2.97e-05	0.000344	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.97e-05	0.000344	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—ovarian cancer	2.94e-05	0.000341	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—ovarian cancer	2.94e-05	0.00034	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.93e-05	0.000339	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BRIP1—ovarian cancer	2.93e-05	0.000339	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.87e-05	0.000333	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK3—ovarian cancer	2.81e-05	0.000326	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.79e-05	0.000323	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—YAP1—ovarian cancer	2.77e-05	0.000321	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.75e-05	0.000318	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FASN—ovarian cancer	2.7e-05	0.000313	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PARP1—ovarian cancer	2.69e-05	0.000311	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYTB—ovarian cancer	2.68e-05	0.00031	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK1—ovarian cancer	2.68e-05	0.00031	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—ovarian cancer	2.68e-05	0.00031	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.64e-05	0.000305	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.62e-05	0.000303	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC2A1—ovarian cancer	2.57e-05	0.000297	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.56e-05	0.000297	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—ovarian cancer	2.53e-05	0.000293	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.51e-05	0.00029	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.51e-05	0.00029	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.51e-05	0.00029	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.41e-05	0.000279	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.37e-05	0.000274	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.34e-05	0.000271	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.34e-05	0.000271	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—FASN—ovarian cancer	2.26e-05	0.000262	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC5A5—ovarian cancer	2.22e-05	0.000258	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PPP2R1A—ovarian cancer	2.18e-05	0.000253	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.18e-05	0.000252	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC2A1—ovarian cancer	2.15e-05	0.000249	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—ovarian cancer	2.15e-05	0.000249	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.11e-05	0.000244	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.1e-05	0.000244	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYTB—ovarian cancer	2.07e-05	0.000239	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1B1—ovarian cancer	2.06e-05	0.000238	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—ovarian cancer	2.06e-05	0.000238	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—YAP1—ovarian cancer	1.97e-05	0.000228	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—ovarian cancer	1.9e-05	0.00022	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.83e-05	0.000211	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.82e-05	0.00021	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.81e-05	0.000209	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.81e-05	0.000209	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.78e-05	0.000206	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—ovarian cancer	1.73e-05	0.000201	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.71e-05	0.000197	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—ovarian cancer	1.7e-05	0.000196	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—ovarian cancer	1.67e-05	0.000193	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FASN—ovarian cancer	1.6e-05	0.000186	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CAV1—ovarian cancer	1.6e-05	0.000186	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.58e-05	0.000183	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—YAP1—ovarian cancer	1.57e-05	0.000182	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.55e-05	0.00018	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.52e-05	0.000176	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6ST—ovarian cancer	1.52e-05	0.000176	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.46e-05	0.000169	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—ovarian cancer	1.46e-05	0.000169	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.37e-05	0.000158	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CAV1—ovarian cancer	1.34e-05	0.000155	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.3e-05	0.00015	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CD—ovarian cancer	1.28e-05	0.000149	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.28e-05	0.000148	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FASN—ovarian cancer	1.28e-05	0.000148	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.26e-05	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—ovarian cancer	1.22e-05	0.000142	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.22e-05	0.000141	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—YAP1—ovarian cancer	1.21e-05	0.00014	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.19e-05	0.000138	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—ovarian cancer	1.18e-05	0.000137	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.17e-05	0.000135	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—ovarian cancer	1.13e-05	0.000131	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CB—ovarian cancer	1.12e-05	0.00013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTOR—ovarian cancer	1.12e-05	0.00013	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CD—ovarian cancer	1.07e-05	0.000124	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—ovarian cancer	1.05e-05	0.000122	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.03e-05	0.00012	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.03e-05	0.000119	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—ovarian cancer	9.92e-06	0.000115	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FASN—ovarian cancer	9.88e-06	0.000114	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC5A5—ovarian cancer	9.72e-06	0.000112	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—ovarian cancer	9.67e-06	0.000112	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—ovarian cancer	9.6e-06	0.000111	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CAV1—ovarian cancer	9.52e-06	0.00011	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—ovarian cancer	9.43e-06	0.000109	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC2A1—ovarian cancer	9.38e-06	0.000109	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CB—ovarian cancer	9.37e-06	0.000108	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1B1—ovarian cancer	9e-06	0.000104	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—ovarian cancer	8.67e-06	0.0001	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—ovarian cancer	8.65e-06	0.0001	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—ovarian cancer	8.63e-06	9.98e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK3—ovarian cancer	8.26e-06	9.56e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—ovarian cancer	8.1e-06	9.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—ovarian cancer	8.03e-06	9.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	7.98e-06	9.24e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK1—ovarian cancer	7.86e-06	9.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—ovarian cancer	7.86e-06	9.1e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CD—ovarian cancer	7.62e-06	8.82e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CAV1—ovarian cancer	7.6e-06	8.79e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—ovarian cancer	7.42e-06	8.59e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—ovarian cancer	7.41e-06	8.58e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—ovarian cancer	7.28e-06	8.42e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.26e-06	8.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—ovarian cancer	6.92e-06	8.01e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—ovarian cancer	6.82e-06	7.89e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CB—ovarian cancer	6.64e-06	7.69e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—ovarian cancer	6.31e-06	7.3e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CD—ovarian cancer	6.08e-06	7.04e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—ovarian cancer	6.04e-06	6.99e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CAV1—ovarian cancer	5.86e-06	6.79e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—ovarian cancer	5.74e-06	6.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—ovarian cancer	5.71e-06	6.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—ovarian cancer	5.57e-06	6.45e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	5.34e-06	6.18e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CB—ovarian cancer	5.3e-06	6.14e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.69e-06	5.43e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—ovarian cancer	4.67e-06	5.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—ovarian cancer	4.58e-06	5.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	4.09e-06	4.74e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—ovarian cancer	4.05e-06	4.69e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—ovarian cancer	3.54e-06	4.09e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—ovarian cancer	3.31e-06	3.83e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—ovarian cancer	3.23e-06	3.74e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—ovarian cancer	2.64e-06	3.06e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.49e-06	2.89e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—ovarian cancer	2.04e-06	2.36e-05	CbGpPWpGaD
